Routine serologic testing for celiac disease may be useful in irritable bowel syndrome (IBS) patients, but this is controversial.
Dr Ann Almazar and colleagues compared the prevalence of unrecognized celiac disease in a large cohort of patients with and without IBS.
The research team conducted this family case–control IBS study conducted at a single US academic medical center.
Stored serum and DNA were available, and the team performed tissue transglutaminase (TTg) immunoglobulin A, followed by indirect immunofluorescence testing for endomysial antibodies with positive or weakly positive TTg results.
Serum samples were studied from 533 cases and 531 controls.
|Previous serological testing for celiac disease had occurred in 27% of cases|
|European Journal of Gastroenterology & Hepatology|
In all, the researchers noted that 80% of participants were female, with a median age of 50 years.
The team observed that 65% of cases and 0% controls met the Rome criteria for IBS.
Previous serological testing for celiac disease had occurred in 27% of cases, and 2% of controls, but none had celiac disease on subsequent testing.
The research team found that 1% of cases versus 0.9% of controls had positive or weakly positive TTg test.
The team observed that 1.1% versus 0.6% of controls were confirmed to have celiac disease by endomysial antibody.
Dr Almazar's team concluded, "No difference in the prevalence of celiac disease between patients with IBS and patients without IBS at a tertiary medical center was observed."
"Our findings do not support routine celiac serologic or genetic testing in patients with IBS in all US populations."